CN113975386A - 嗜酸性粒细胞或肥大细胞相关病症的治疗 - Google Patents

嗜酸性粒细胞或肥大细胞相关病症的治疗 Download PDF

Info

Publication number
CN113975386A
CN113975386A CN202111229451.9A CN202111229451A CN113975386A CN 113975386 A CN113975386 A CN 113975386A CN 202111229451 A CN202111229451 A CN 202111229451A CN 113975386 A CN113975386 A CN 113975386A
Authority
CN
China
Prior art keywords
seq
antibody
kit
antibody comprises
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111229451.9A
Other languages
English (en)
Chinese (zh)
Inventor
特丽萨·玛丽·拉瓦雷
杰拉尔德·麦克马洪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celldex Therapeutics Inc
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Publication of CN113975386A publication Critical patent/CN113975386A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202111229451.9A 2014-05-23 2015-05-22 嗜酸性粒细胞或肥大细胞相关病症的治疗 Pending CN113975386A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462002395P 2014-05-23 2014-05-23
US62/002,395 2014-05-23
US201562162538P 2015-05-15 2015-05-15
US62/162,538 2015-05-15
CN201580040042.0A CN106659782B (zh) 2014-05-23 2015-05-22 一种用于嗜酸性粒细胞或肥大细胞相关病症治疗的抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580040042.0A Division CN106659782B (zh) 2014-05-23 2015-05-22 一种用于嗜酸性粒细胞或肥大细胞相关病症治疗的抗体

Publications (1)

Publication Number Publication Date
CN113975386A true CN113975386A (zh) 2022-01-28

Family

ID=54554980

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202111229451.9A Pending CN113975386A (zh) 2014-05-23 2015-05-22 嗜酸性粒细胞或肥大细胞相关病症的治疗
CN201580040042.0A Active CN106659782B (zh) 2014-05-23 2015-05-22 一种用于嗜酸性粒细胞或肥大细胞相关病症治疗的抗体
CN202111229223.1A Pending CN113908269A (zh) 2014-05-23 2015-05-22 嗜酸性粒细胞或肥大细胞相关病症的治疗

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201580040042.0A Active CN106659782B (zh) 2014-05-23 2015-05-22 一种用于嗜酸性粒细胞或肥大细胞相关病症治疗的抗体
CN202111229223.1A Pending CN113908269A (zh) 2014-05-23 2015-05-22 嗜酸性粒细胞或肥大细胞相关病症的治疗

Country Status (5)

Country Link
US (4) US10239943B2 (https=)
EP (1) EP3145543A4 (https=)
JP (3) JP6768639B2 (https=)
CN (3) CN113975386A (https=)
WO (1) WO2015179737A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
CN113975386A (zh) * 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
JP2019527227A (ja) * 2016-07-19 2019-09-26 アレート ディスカバリーズ インコーポレイテッド マスト細胞活性関連障害の検出および処置のためのバイオマーカー
US11167023B2 (en) * 2018-12-28 2021-11-09 DANCLAY Properties, LLC Method of treating mammals displaying severe neurological symptoms of advanced canine distemper virus infection using NDV-induced serum
US20240117057A1 (en) * 2021-01-22 2024-04-11 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2022159744A1 (en) * 2021-01-22 2022-07-28 Celldex Therapeutics, Inc. Treatment of chronic prurigo
WO2022182982A1 (en) * 2021-02-26 2022-09-01 Third Harmonic Bio, Inc. Methods for treating c-kit kinase mediated diseases and disorders using a selective c-kit kinase inhibitor

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003302A2 (en) * 2003-06-17 2005-01-13 Medimmune, Inc. Novel methods to modulate mast cells
US20060058339A1 (en) * 2004-06-17 2006-03-16 Ibrahim Prabha N Compounds modulating c-kit activity and uses therefor
CN101472949A (zh) * 2006-04-24 2009-07-01 安姆根有限公司 人源化c-Kit抗体
US20100267777A1 (en) * 2007-01-19 2010-10-21 Bayer Pharmaceuticals Corporation Treatment of cancers with acquired resistance to kit inhibitors
US20100291073A1 (en) * 2007-05-14 2010-11-18 Medimmune, Llc Methods of reducing eosinophil levels
CN106659782A (zh) * 2014-05-23 2017-05-10 科尔坦制药公司 嗜酸性粒细胞或肥大细胞相关病症的治疗

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268358A (en) 1988-12-08 1993-12-07 Cor Therapeutics, Inc. PDGF receptor blocking peptides
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US20030125519A1 (en) 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
US20050276784A1 (en) 1990-08-27 2005-12-15 Solan-Kettering Institute For Cancer Research Ligand for the c-kit receptor and methods of use thereof
DK0584082T3 (da) 1991-01-31 2000-10-16 Univ California Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider
EP0578774B1 (en) 1991-04-05 1998-07-29 The Board Of Regents Of The University Of Washington Monoclonal antibodies to stem cell factor receptors
DE4205148A1 (de) 1991-05-25 1993-01-21 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen c-kit
US5545533A (en) 1991-05-25 1996-08-13 Boehringer Mannheim Gmbh Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
NZ246242A (en) 1991-12-02 1996-01-26 Cor Therapeutics Inc Inhibiting immunoglobulins acting on beta-platelet derived growth factor (pdgf)
EP0548867A2 (en) 1991-12-23 1993-06-30 Yeda Research And Development Co. Ltd. Soluble stem cell factor (SFC)-receptor
US6001803A (en) 1992-04-23 1999-12-14 Sloan-Kettering Institute For Cancer Research Composition of c-kit ligand, GM-CSF, and TNF-α and method of use
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5911988A (en) 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
US6936259B2 (en) 1995-06-08 2005-08-30 University Of Saskatchewan CAMP factor of Streptococcus uberis
DE19600589C1 (de) 1996-01-10 1997-01-16 Univ Eberhard Karls Antikörper A3C6E2
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5910417A (en) 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
AU6763098A (en) 1997-03-19 1998-10-12 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
DE19727814C1 (de) 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6555367B1 (en) 1997-10-10 2003-04-29 The United States Of America As Represented By The Department Of Health And Human Services Complex of biotinylated viral vector and ligand for targeted gene delivery
EP1169352A4 (en) 1999-04-14 2005-05-04 Smithkline Beecham Corp ANTIBODY AGAINST THE ERYTHROPOIETIN RECEPTOR
US6989248B2 (en) 1999-05-06 2006-01-24 The Trustees Of Columbia University In The City Of New York Methods of use of compounds which inhibit the stem cell signaling pathway
US6576812B1 (en) 1999-05-06 2003-06-10 The Trustees Of Columbia University In The City Of New York Compound screening assays using a transgenic mouse model of human skin diseases
WO2001034201A2 (en) 1999-11-12 2001-05-17 Advanced Research And Technology Institute, Inc. Methods for inhibiting neurofibromatosis type 1 (nf1)
ATE331514T1 (de) * 1999-12-22 2006-07-15 Sugen Inc Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20110091428A1 (en) 2000-07-31 2011-04-21 New York Medical College Compositions of adult organ stem cells and uses thereof
US6914947B2 (en) 2001-02-28 2005-07-05 Telefonaktiebolaget L M Ericsson (Publ) Method and apparatus for handling time-drift
EP1378752A4 (en) 2001-04-13 2004-08-04 Chugai Pharmaceutical Co Ltd METHOD FOR QUANTIFYING ANTIGEN EXPRESSION
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
WO2003016867A2 (en) 2001-08-21 2003-02-27 Ventana, Medical, Systems, Inc Method and quantification assay for determining c-kit/scf/pakt status
AU2002361784A1 (en) 2001-12-20 2003-07-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2003237332A1 (en) 2002-06-03 2003-12-19 Centocor, Inc. Anti-relp fusion antibodies, compositions, methods and uses
AU2003245752A1 (en) 2002-06-28 2004-01-19 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
ATE552860T1 (de) 2003-01-31 2012-04-15 Celldex Res Corp Antikörper-vakzine-konjugate und ihre verwendungen
US20050281828A1 (en) 2003-03-04 2005-12-22 Bowdish Katherine S Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
US7303893B1 (en) 2003-08-28 2007-12-04 Takeda San Diego, Inc. Crystallization of c-KIT tyrosine kinase leading to autoinhibited crystal structure
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
EP1690097A2 (en) 2003-12-04 2006-08-16 Applied Research Systems ARS Holding N.V. Methods for identifying modulators of active kit tyrosine kinase receptor
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
US7803535B2 (en) 2004-03-27 2010-09-28 Hanns-Georg Klein Polymorphisms in the NOD2/CARD15 gene
ES2375481T3 (es) 2004-03-30 2012-03-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticuerpos biespecíficos para elegir como diana células que participan en reacciones de tipo alérgico, composiciones y usos de los mismos.
BRPI0510716A (pt) 2004-05-05 2007-11-20 Merrimack Pharmaceuticals Inc uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
CA2573293A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
AU2005269265B2 (en) 2004-08-02 2012-01-12 Zenyth Operations Pty Ltd A method of treating cancer comprising a VEGF-B antagonist
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
CA2599606A1 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US20060222634A1 (en) 2005-03-31 2006-10-05 Clarke Diana L Amnion-derived cell compositions, methods of making and uses thereof
PL1874821T3 (pl) 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka
WO2007004060A2 (en) 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
US20090136450A1 (en) 2005-08-01 2009-05-28 Ares Trading S.A. Therapy for neurological diseases
EP1948827B1 (en) 2005-10-21 2016-03-23 The Regents of The University of California C-kit oncogene mutations in melanoma
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US20090304625A1 (en) 2006-01-18 2009-12-10 Ahsan Husain Modulators of cardiac cell hypertrophy and hyperplasia
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
CA2644143C (en) 2006-04-05 2013-10-01 Novartis Ag Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
EP2076266A2 (en) 2006-05-31 2009-07-08 The Board of Trustees of the Leland Stanford Junior University Method of treating inflammatory diseases using tyroskine kinase inhibitors
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
CA2666789C (en) 2006-10-18 2016-11-22 Yong Zhao Embryonic-like stem cells derived from adult human peripheral blood and methods of use
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
WO2008051757A1 (en) 2006-10-20 2008-05-02 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
WO2008067115A2 (en) 2006-11-03 2008-06-05 The Board Of Trustees Of The Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
WO2008059052A1 (en) 2006-11-17 2008-05-22 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
US20100143935A1 (en) 2006-12-01 2010-06-10 Apocell, Inc. c-KIT Phosphorylation in Cancer
CN101932604A (zh) 2007-03-12 2010-12-29 瓦斯基因治疗公司 EphB4作为诊断标记和作为卵巢癌的治疗靶标的用途
EP2155694B1 (en) 2007-03-27 2012-01-04 Synta Pharmaceuticals Corp. Triazinone and diazinone derivatives useful as hsp90 inhibitors
US20110268776A1 (en) 2007-04-25 2011-11-03 Schapira Jay N Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CA2687896A1 (en) 2007-06-05 2008-12-18 Yale University Antibody directed against the d4 ig-like domain of the kit receptor
JP5703466B2 (ja) 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
US20100196923A1 (en) 2007-08-14 2010-08-05 Anthony Atala Pluripotent adult stem cells
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
JP2011504926A (ja) 2007-11-28 2011-02-17 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド Ｅｇｆｒキナーゼ阻害剤とｃ−ｋｉｔ阻害剤による併用治療
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2009079585A2 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
WO2009100105A2 (en) 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof
WO2009135001A2 (en) 2008-04-30 2009-11-05 University Of Pittsburgh- Commonwealth System Of Higher Education Methods and compositions for regulating th2 and th17 responses
WO2009140452A2 (en) 2008-05-15 2009-11-19 University Of Miami Isolation of stem cell precursors and expansion in non-adherent conditions
KR20110025827A (ko) 2008-06-13 2011-03-11 노파르티스 아게 신경섬유종증을 위한 치환된 벤즈이미다졸
EP2291186A4 (en) * 2008-06-27 2011-06-22 Univ Indiana Res & Tech Corp MATERIALS AND METHODS OF SUPPRESSING AND / OR TREATING NEUROFIBROME AND RELATED TUMORS
CA2729567C (en) 2008-06-30 2018-04-24 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
WO2010036373A2 (en) 2008-09-26 2010-04-01 Duke University Hematopoietic stem cell growth factor
AU2009307651A1 (en) 2008-10-22 2010-04-29 Genentech, Inc. Prostate stem cells and uses thereof
AU2009316541B2 (en) 2008-11-19 2015-08-06 Celularity Inc. Amnion derived adherent cells
WO2010065685A1 (en) 2008-12-04 2010-06-10 Cleveland Clinic Method of treating c-kit positive relapsed acute myeloid leukemia
US20100204058A1 (en) 2009-01-28 2010-08-12 Howard Yuan-Hao Chang Profiling for Determination of Response to Treatment for Inflammatory Disease
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
NZ596274A (en) 2009-05-12 2013-11-29 Pfizer Blocking anti-dkk-1 antibodies and their uses
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
BRPI1013177A2 (pt) 2009-05-28 2016-04-12 Glaxo Group Ltd construto de ligação de antígeno, polipeptídeo isolado, e, método para tratar doença cardíaca
CN106220623A (zh) * 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
KR20120115348A (ko) 2009-12-29 2012-10-17 예일 유니버시티 혈관 내피 성장 인자 (ｖｅｇｆ) 수용체의 억제제 및 그의 사용 방법
RU2012134637A (ru) 2010-01-14 2014-02-20 Йейл Юниверсити Ингибиторы рецепторных тирозинкиназ (rtk) и способы их применения
WO2011119948A1 (en) 2010-03-26 2011-09-29 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
IN2013MN01394A (https=) 2011-01-06 2015-06-12 Complix Nv
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
AR086044A1 (es) * 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
BR112014009050B1 (pt) 2011-10-14 2022-06-21 Medimmune Limited Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
WO2015112822A1 (en) 2014-01-24 2015-07-30 Kolltan Pharmaceuticals, Inc. Antibody-drug conjugates targeting kit receptor and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003302A2 (en) * 2003-06-17 2005-01-13 Medimmune, Inc. Novel methods to modulate mast cells
US20060058339A1 (en) * 2004-06-17 2006-03-16 Ibrahim Prabha N Compounds modulating c-kit activity and uses therefor
CN101472949A (zh) * 2006-04-24 2009-07-01 安姆根有限公司 人源化c-Kit抗体
US20100267777A1 (en) * 2007-01-19 2010-10-21 Bayer Pharmaceuticals Corporation Treatment of cancers with acquired resistance to kit inhibitors
US20100291073A1 (en) * 2007-05-14 2010-11-18 Medimmune, Llc Methods of reducing eosinophil levels
CN106659782A (zh) * 2014-05-23 2017-05-10 科尔坦制药公司 嗜酸性粒细胞或肥大细胞相关病症的治疗

Also Published As

Publication number Publication date
EP3145543A2 (en) 2017-03-29
JP2021006543A (ja) 2021-01-21
CN106659782B (zh) 2021-11-09
JP6768639B2 (ja) 2020-10-21
WO2015179737A2 (en) 2015-11-26
US20190153094A1 (en) 2019-05-23
US10239943B2 (en) 2019-03-26
US20220056127A1 (en) 2022-02-24
WO2015179737A3 (en) 2016-01-14
CN113908269A (zh) 2022-01-11
JP7846960B2 (ja) 2026-04-16
US11987626B2 (en) 2024-05-21
US20240287180A1 (en) 2024-08-29
JP2017517568A (ja) 2017-06-29
JP2023154065A (ja) 2023-10-18
EP3145543A4 (en) 2017-12-13
US10774146B2 (en) 2020-09-15
US20170121408A1 (en) 2017-05-04
CN106659782A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
US20240287180A1 (en) Treatment of eosinophil or mast cell related disorders
KR102662228B1 (ko) 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
KR20170004006A (ko) 암을 치료하기 위한 항-ｃｃｒ4 항체 및 4-1ｂｂ 효능제의 조합
KR20130135872A (ko) 중화 항-ccl20 항체
WO2022191306A1 (ja) 重症筋無力症の治療または予防用の医薬組成物
KR20180081522A (ko) 신경계 및 다른 장애의 치료를 위한 결합 효능제
US20250230235A1 (en) Treatment of mast cell related disorders
JP2023550554A (ja) 腸がんの処置のための組成物及び方法
KR101898982B1 (ko) 골관절염 치료
US20240109961A1 (en) Treatment of chronic prurigo
KR20250167153A (ko) 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물
EP4506366A1 (en) Antigen-binding protein targeting pd-l1 and cd40, preparation therefor, and use thereof
JP7824946B2 (ja) アトピー性皮膚炎又は関連症状を治療及び／又は防止するためのｉｌ－１８アンタゴニストの使用
US20260078181A1 (en) Trem-2 agonists for the treatment of marfan syndrome
RU2847150C1 (ru) Применение антагониста il-18 для лечения и/или предупреждения атопического дерматита или связанного с ним состояния
CN117120089A (zh) 慢性痒疹的治疗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination